A phase I/II study of pixantrone (BBR 2778) in patients with refractory acute myelogenous leukemia (AML)

Trial Profile

A phase I/II study of pixantrone (BBR 2778) in patients with refractory acute myelogenous leukemia (AML)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2014

At a glance

  • Drugs Pixantrone (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CTI BioPharma
  • Most Recent Events

    • 21 Aug 2007 Status change from in progress to completed.
    • 26 Jul 2007 The expected completion date for this trial is now 1 Mar 2007.
    • 22 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top